Galvus Met 50mg / 850mg 30 tablets

Galvus met

Each tablet contains:

 Vildagliptin 50mg

 Metformin hydrochloride 850mg

Auxiliary components:

Hydroxypropyl cellulose, hyprollosis, iron oxide yellow, iron oxide red, macrogol, magnesium stearate, talc and titanium dioxide.

Combined oral hypoglycemic agent.

Vildagliptin, a member of the class of stimulants of the islet apparatus of the pancreas, selectively inhibits the DPP-4 enzyme, improving glycemic control. Inhibition of DPP-4 activity causes an increase in both basal and postprandial endogenous levels of incretin hormones: glucagon-like peptide type 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

Metformin reduces the production of glucose by the liver, reduces the absorption of glucose in the intestine and reduces insulin resistance by enhancing the uptake and utilization of glucose by peripheral tissues. Metformin induces intracellular glycogen synthesis by acting on glycogen synthetase and enhances glucose transport by some membrane glucose transport proteins (GLUT-1 and GLUT-4). Improves glucose tolerance in patients with type 2 diabetes mellitus by lowering plasma glucose concentrations both before and after meals. Unlike sulfonylurea derivatives, metformin does not cause hypoglycemia either in patients with type 2 diabetes mellitus or in healthy individuals (except in special cases). Metformin does not lead to the development of hyperinsulinemia. When metformin is used, insulin secretion does not change,

The combination of these components makes it possible to more effectively control the blood glucose concentration in patients with type 2 diabetes mellitus within 24 hours.

Type 2 diabetes mellitus (in combination with diet and exercise)

The method of application and dosage regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the used dosage form of a particular drug with the indications for use and the dosage regimen. When using this combination, the recommended maximum daily dose of vildagliptin of 100 mg should not be exceeded. The maximum daily dose of metformin is from 500 mg to 2000 mg per day.

Type 1 diabetes mellitus; renal failure or severe renal impairment with GFR <30 ml / min; acute conditions with a risk of developing renal dysfunction: dehydration (with diarrhea, vomiting), fever, severe infectious diseases, hypoxic conditions (shock, sepsis, kidney infections, bronchopulmonary diseases); acute and chronic heart failure, acute myocardial infarction, acute cardiovascular failure (shock), respiratory failure; liver dysfunction; acute or chronic metabolic acidosis (including diabetic ketoacidosis with or without coma); lactic acidosis (including history); should not be used 48 hours before surgery, radioisotope, X-ray examinations with the introduction of contrast agents and within 48 hours after their implementation; chronic alcoholism, acute alcohol poisoning; adherence to a low-calorie diet (less than 1000 kcal / day); pregnancy, lactation (breastfeeding); children under 18 years of age; hypersensitivity to vildagliptin or metformin or any other components of the drug.

Preparations containing metformin are recommended to be used with caution in patients over 60 years of age when performing heavy physical work, due to the increased risk of lactic acidosis in them.

In patients receiving insulin treatment, this combination cannot replace insulin therapy.

Regularly during treatment with the drug, it is recommended to determine the biochemical parameters of liver function. If an increase in the activity of aminotransferases is detected, a second study should be carried out in order to confirm the result, and then the biochemical parameters of liver function should be regularly determined until they are normalized. If an excess of the activity of AST or ALT is 3 or more times higher than the ULN confirmed by a repeated study, it is recommended to cancel the treatment.

From the nervous system: often – headache, dizziness, tremors. When vildagliptin was used in combination with metformin at various doses, hypoglycemia was observed in 0.9% of cases (for comparison, in the placebo group in combination with metformin – in 0.4%).

From the digestive system: often – nausea, gastroesophageal reflux, dysgeusia; infrequently – diarrhea, flatulence; very rarely – hepatitis.

From the side of metabolism and nutrition: very often – decreased appetite; often hypoglycemia; very rarely – lactic acidosis.

Infectious and parasitic diseases: very rarely – upper respiratory tract infections, nasopharyngitis.

General disorders and disorders at the injection site: often – chills.

On the part of the skin and subcutaneous tissues: often – hyperhidrosis; very rarely – skin reactions (in particular, erythema, pruritus, urticaria).

Musculoskeletal and connective tissue disorders: often – arthralgia.

From the side of the vessels: infrequently – peripheral edema.

In a cool dry place at a temperature not exceeding 25 degrees.

The cardboard box contains 3 blisters of 10 tablets, paper instructions.